Stock Events

Stock Events

BlackRock Technology and Private Equity Term Trust 

$8.20
116
-$0.14-1.68% Friday 19:59
+$0.00+0%Friday 20:03After hours

Statistics

Day High
8.2
Day Low
8.19
52W High
9.44
52W Low
6.13
Volume
15,147
Avg. Volume
-
Mkt Cap
9.56M
P/E Ratio
23.38
Dividend Yield
7.68%
Dividend
0.63

Upcoming

31
JUL
Dividend Payment
 
14
AUG
Dividend Ex
 
31
AUG
Dividend Payment
 
15
SEP
Dividend Ex
 
30
SEP
Dividend Payment
 

Dividends

7.68%Dividend Yield
Jul 26
$0.05
Jun 26
$0.05
May 26
$0.05
Apr 26
$0.05
Mar 26
$0.05
10Y Growth
N/A
5Y Growth
-2.09%
3Y Growth
-6.3%
1Y Growth
-30.11%

Earnings

17AugExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Next
-6.95
-5.28
-3.62
-1.95
Expected EPS
-3.3
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-14.1MNet Income

Analyst Ratings

30.00Average Price Target
The highest estimate is 30.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow BTX. It's not an investment recommendation.
Schwab US Dividend Equity
23
SCHD
Realty Income
22
O
NVIDIA
22
NVDA
JPMorgan Equity Premium Income
22
JEPI

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap5.25B
CRISPR Therapeutics is a leader in the development of gene-based therapies, directly competing with Eterna's focus on mRNA and gene editing technologies.
Editas Medicine
EDIT
Mkt Cap500.29M
Editas Medicine operates in the gene editing space, making it a direct competitor to Eterna Therapeutics in the development of gene therapy solutions.
Intellia Therapeutics
NTLA
Mkt Cap1.99B
Intellia Therapeutics is another key player in the CRISPR/Cas9 gene editing technology, competing in the same space as Eterna Therapeutics.
Beam Therapeutics
BEAM
Mkt Cap3.36B
Beam Therapeutics uses base editing, a form of gene editing, positioning it as a competitor in the gene therapy market alongside Eterna Therapeutics.
Sangamo Therapeutics
SGMO
Mkt Cap30.66M
Sangamo Therapeutics focuses on genomic medicine, including gene editing and gene therapy, competing with Eterna in the development of genetic treatments.
Alnylam Pharmaceuticals
ALNY
Mkt Cap39.89B
Alnylam Pharmaceuticals is a leader in RNAi (RNA interference) therapeutics, competing with Eterna's focus on mRNA therapies.
Ionis Pharmaceuticals
IONS
Mkt Cap9.63B
Ionis Pharmaceuticals specializes in RNA-targeted drug discovery and development, making it a competitor in the RNA space with Eterna.
Biomarin Pharmaceutical
BMRN
Mkt Cap11.43B
BioMarin Pharmaceutical focuses on enzyme replacement therapies, which can be seen as complementary or competitive to gene therapies offered by Eterna.
Vertex Pharmaceuticals
VRTX
Mkt Cap123.19B
Vertex Pharmaceuticals, with its focus on treating genetic diseases, competes in the broader market for genetic therapies that Eterna is also targeting.

About

BlackRock Technology and Private Equity Term Trust is a mutual fund launched by BlackRock, Inc. The fund is managed by BlackRock Advisors, LLC. BlackRock Technology and Private Equity Term Trust is domiciled in the United States.
Show more...
CEO
Dr. Roger Sidhu M.D.
Employees
11
Country
United States

Listings

XNYS
US
BTX
XNAS
US
ERNA
XNAS
US
ERNAW
BOATS
BOATS
ERNA.BOATS

1 Comments

Share your thoughts

FAQ

What is BlackRock Technology and Private Equity Term Trust stock price today?▼
The current price of BTX is $8.20 USD — it has decreased by -1.68% in the past 24 hours. Watch BlackRock Technology and Private Equity Term Trust stock price performance more closely on the chart.
What is BlackRock Technology and Private Equity Term Trust stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNYS exchange BlackRock Technology and Private Equity Term Trust stocks are traded under the ticker BTX.
What is BlackRock Technology and Private Equity Term Trust market cap?▼
Today BlackRock Technology and Private Equity Term Trust has the market capitalization of 9.56M
When is the next BlackRock Technology and Private Equity Term Trust earnings date?▼
BlackRock Technology and Private Equity Term Trust is going to release the next earnings report on August 17, 2026.
What were BlackRock Technology and Private Equity Term Trust earnings last quarter?▼
BTX earnings for the last quarter are -6.95 USD per share, whereas the estimation was -1.95 USD resulting in a -256.41% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is BlackRock Technology and Private Equity Term Trust revenue for the last year?▼
BlackRock Technology and Private Equity Term Trust revenue for the last year amounts to 0 USD.
What is BlackRock Technology and Private Equity Term Trust net income for the last year?▼
BTX net income for the last year is -14.1M USD.
Does BlackRock Technology and Private Equity Term Trust pay dividends?▼
Yes, BTX dividends are paid monthly. The last dividend per share was 0.05 USD. As of today, Dividend Yield (FWD)% is 7.68%.
How many employees does BlackRock Technology and Private Equity Term Trust have?▼
As of July 27, 2026, the company has 11 employees.
In which sector is BlackRock Technology and Private Equity Term Trust located?▼
BlackRock Technology and Private Equity Term Trust operates in the Health & Wellness sector.
When did BlackRock Technology and Private Equity Term Trust complete a stock split?▼
The last stock split for BlackRock Technology and Private Equity Term Trust was on May 04, 2026 with a ratio of 1:25.
Where is BlackRock Technology and Private Equity Term Trust headquartered?▼
BlackRock Technology and Private Equity Term Trust is headquartered in New York, United States.